Market Watch: Vulcan Materials Company (NYSE:VMC), Multi-Fineline Electronix (NASDAQ:MFLX), Joy Global (NYSE:JOY), Dr Pepper Snapple Group (NYSE:DPS), Pharmacyclics (NASDAQ:PCYC)

On 13 February, Vulcan Materials Company (NYSE:VMC) announced that it has elected Elaine L. Chao and Thomas A. Fanning to its Board of Directors, effective immediately. On Tuesday shares of Vulcan Materials Company (NYSE:VMC) closed at $80.76. Company’s sales growth for last 5 years was 2.20% and EPS growth for next 5 years is recorded as 9.00%.

On 11 February, Multi-Fineline Electronix, Inc. (NASDAQ: MFLX), announced the appointment of Hong Wai Chan, 53, to the Company’s Board of Directors as a non-independent director. Multi-Fineline Electronix, Inc. (NASDAQ:MFLX) in last trading activity advanced 7.81% to close at $16.16. Company weekly performance is 7.23% while its quarterly performance stands at 51.31%. Multi-Fineline Electronix, Inc. (NASDAQ:MFLX) is 5.28% away from its 52 week high.

Joy Global (NYSE:JOY) had its price objective cut by Citigroup Inc. from $54.00 to $50.00 in a research report released on Monday morning. Citigroup Inc. currently has a neutral rating on the stock. On last trading day Joy Global, Inc. (NYSE:JOY) advanced 0.34% to close at $44.29. Its volatility for the week is 2.57% while volatility for the month is 2.43%. JOY’s sales growth for past 5 years was 1.00% and its EPS growth for past 5 years was -5.70%. Joy Global, Inc. (NYSE:JOY) monthly performance is 4.48%.

Dr Pepper Snapple Group (NYSE:DPS) declared a quarterly dividend of $0.48 per share on the company’s common stock a 17.1% increase in the dividend rate. The dividend is payable in U.S. dollars on April 7, 2015, to shareholders of record as of close of business on March 16, 2015. Dr Pepper Snapple Group, Inc. (NYSE:DPS) has 0.20% insider ownership while its institutional ownership stands at 98.20%. In last trading activity company’s stock closed at $77.07.

Pharmacyclics Inc. (NASDAQ: PCYC) announced that treatment with IMBRUVICA (ibrutinib) was associated with an 88% overall response rate (ORR), with a median time on study of 23.3 months, in 16 patients with relapsed/refractory (R/R) high-risk chronic lymphocytic leukemia (CLL). On last trading day Pharmacyclics Inc. (NASDAQ:PCYC) advanced 2.39% to close at $167.18. Its volatility for the week is 3.04% while volatility for the month is 4.27%. PCYC’s EPS growth for past 5 years was 24.50%. Pharmacyclics Inc. (NASDAQ:PCYC) monthly performance is 16.71%.

Leave a Reply

Your email address will not be published. Required fields are marked *

*